Close Menu

Group B Streptococcus

In 2018 Qiagen purchased a 19.9 percent stake in Ann Arbor, Michigan-based NeuMoDx along with the right to acquire the remaining shares.

The firm aims to stabilize and protect its existing molecular diagnostics business over the next 12 to 18 months, CEO Jack Kenny said.

In PLOS this week: novel loci linked to QRS duration in Hispanic/Latino populations, group B Streptococcus in Southeast Asia, and more.

NEW YORK (GenomeWeb) — IntelligentMDx (IMDx) said today that the artus GBS QS-RGQ kit, developed in partnership with Qiagen, has received CE marking for use with Qiagen's QIAsymphony SP/AS and Rotor-Gene Q instruments.

NEW YORK (GenomeWeb News) – Quidel said after the close of the market on Monday that the US Food and Drug Administration has cleared the company's AmpliVue Group B Strep Assay, the second assay to receive FDA clearance to run on the AmpliVue handheld molecular testing platform.

Researchers last week provided a glimpse of the clinical performance of a trio of extraction-free molecular assays currently being developed by clinical diagnostics firm Quidel.

NEW YORK (GenomeWeb News) – Meridian Bioscience said on Monday that its illumigene Group A Streptococcus and illumigene Group B Streptococcus assays have been recategorized by the US Food and Drug Administration as "moderate complexity" tests under the Clinical Laboratory Improv

Meridian Bioscience's Illumigene nucleic acid amplification test for Streptococcus pyogenes, or Group A Streptococcus, has a clinical sensitivity of 99 percent and specificity of 99.6 percent when compared to the diagnostic gold standard of culture and discrepan

Meridian Bioscience said today that its Illumigene molecular diagnostic products accounted for 16 percent of its fiscal first quarter revenues, which increased 13 percent over the same quarter last year.

Canadian molecular diagnostics firm GenePOC has completed technical development of its benchtop, point-of-care molecular diagnostic system and disposable test cartridges, and has commenced clinical feasibility studies of the platform, company executives said this week.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.